预约演示
更新于：2025-01-13
Lipoic acid
硫辛酸
更新于：2025-01-13
概要
基本信息
原研机构- |
最高研发阶段批准上市 |
首次获批日期 德国 (1966-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C8H14O2S2 |
InChIKeyAGBQKNBQESQNJD-SSDOTTSWSA-N |
CAS号1200-22-2 |
关联
176
项与 硫辛酸 相关的临床试验NCT05713799
Phase II Trial of the Combination of Alpha-lipoic Acid and Mirabegron in Women and in Men With Obesity
NCT06286098
Effect of Alpha Lipoic Acid on the Clinical Outcome of Pediatric Patients Undergoing Hemodialysis
NCT05083546
Testing the Impact of a Combination of Dietary Supplements With Multimodal Effects on Longevity Mechanisms on Reducing Body Weight and Delaying Aging
100 项与 硫辛酸 相关的临床结果
登录后查看更多信息
100 项与 硫辛酸 相关的转化医学
登录后查看更多信息
100 项与 硫辛酸 相关的专利（医药）
登录后查看更多信息
7,199
项与 硫辛酸 相关的文献（医药）2025-12-01Current Urology Reports
Management Strategies for Patients with Non-Infectious Cystitis: A Review of the Literature
Review
作者: Sawyer, Kathryn ; Zheng, Yu ; Gupta, Priyanka ; Aqeel, Jawad
PURPOSE OF REVIEW:
The management of noninfectious cystitis continues to evolve as new treatments continue to be developed and investigated. This review aims to synthesize the most recent data regarding management strategies for noninfectious cystitis focused on non-ulcerative, ulcerative, eosinophilic, and ketamine-induced cystitis.
RECENT FINDINGS:
Several novel treatments have shown promise as management options including combination antihistamine therapy, phosphodiesterase 5 inhibitors, alpha lipoic acid supplements, and onabotulinumtoxin A. Recent studies have also found pentosan polysulfate sodium to have adverse ophthalmologic effects. For patients with ulcerative cystitis, recent research has shown that fulguration with or without triamcinolone injections should not be delayed. The treatment of noninfectious cystitis should be patient specific based on factors including etiology and symptom profile. Multimodal regimens are often the most effective. Treatment should be started with conservative options and escalated as necessary to oral treatments, intravesical options, or procedural management.
2025-03-01JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
Anticancer effects of alpha-lipoic acid, a potent organosulfur compound by modulating matrix metalloproteinases and apoptotic markers in osteosarcoma MG-63 cells
Article
作者: Soukhtanloo, Mohammad ; Ahmadi, Abdolreza ; Hosseini, Fatemehsadat ; Rostami, Mehdi
Osteosarcoma (OS), an extremely aggressive form of bone tumor primarily affects young adults. Despite significant advancements in clinical trials, the ability of cancer cells to metastasize and resist apoptosis remains a major challenge. To address these issues, novel therapeutic interventions with high specificity for these processes are essential. Alpha-lipoic acid (ALA), an organosulfur compound derived from octanoic acid, possesses a range of pharmacological properties. This study hypothesizes that ALA would inhibit metastasis and induce cell apoptosis in OS. To evaluate the potential of ALA, its effects on the migration, metastasis, and cell cycle of MG-63 OS cells were assessed, along with its ability to trigger apoptosis. To these aims, MG-63 cells were exposed to varying concentrations of ALA, and cell viability was measured using the alamarBlue assay. The impact of ALA on cell cycle progression, apoptosis, migration, and metastasis was analyzed through flow cytometry, scratch assay, and gelatin zymography. After validating the expression of MMP2, MMP9, VEGF, VEGFR, BAX, BCL-2, and P53 by the GEO database, the expression levels of these genes were examined through quantitative PCR (qPCR). Eventually, molecular docking was employed to simulate the interactions between ALA and matrix metalloproteinase (MMPs). The results demonstrated that ALA significantly inhibited cell migration, induced cell cycle arrest, and promoted apoptosis by upregulating P53 and BAX expression while downregulating BCL-2 levels. Furthermore, ALA was found to suppress the activity and expression of MMP2 and MMP9 and reduce the expression of angiogenesis markers. Notably, ALA interacted directly with the active site of MMP2 and MMP9. These findings suggest that ALA has the potential to be a promising agent with anti-cancer effects on MG-63 cells, warranting further preclinical investigations.
2025-02-01NEUROCHEMICAL RESEARCH
Ferroptosis in the Substantia Nigra Pars Compacta of Mice: Triggering Role of Ultrafine Diesel Exhaust Particles and Mitigation by α-Lipoic Acid
Article
作者: Kim, Ji Young ; Seo, Je Hoon ; Kim, Yong-Dae ; Shin, Dong-Ick ; Kim, Aryun ; Gil, Young-Chun ; Kim, Jin-Hee
Recent epidemiological and experimental studies have increasingly highlighted the association between environmental pollution, especially ultrafine particulate matter (PM), and the risk of neurodegenerative diseases, such as Parkinson's disease (PD). These previous studies suggest a potential mechanism by which ultrafine PM contributes to neuronal damage through processes, such as iron accumulation and oxidative stress. In this study, we aimed to elucidate the effects of ultrafine PM on ferroptosis, an iron-dependent form of cell death, in the mouse substantia nigra pars compacta (SNc) and to evaluate the protective role of α-lipoic acid (ALA). Mice were exposed to ultrafine diesel exhaust particles (ufDEP), a type of ultrafine PM, intranasally and injected ALA intraperitoneally for seven consecutive days. Iron accumulation and lipid peroxidation were significantly increased, and antioxidant capacity was significantly decreased in the SNc after ufDEP exposure, highlighting the deleterious effects of ufDEP on tyrosine hydroxylase (TH)-positive neurons. In contrast, ALA treatment effectively mitigated these effects by reducing iron accumulation, decreasing lipid peroxidation, and restoring antioxidant levels, resulting in the protection of TH-positive neurons from ferroptotic damage. Our results provide evidence that ufDEP can induce ferroptosis in dopaminergic neurons in the SNc, potentially contributing to PD pathogenesis. Furthermore, ALA showed protective effects against ufDEP-induced ferroptotic damage, suggesting its potential as a therapeutic intervention for PD.
100 项与 硫辛酸 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 糖尿病性神经病变 | 德国 | - | 1966-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 糖尿病 | 临床3期 | 中国 | - | |
| 寻常痤疮 | 临床2期 | 中国 | 2019-07-11 | |
| 糖尿病周围神经病变 | 临床1期 | 中国 | 2021-07-08 | |
| 2型糖尿病 | 临床前 | 卡塔尔 | 2019-09-17 | |
| 胰岛素抵抗 | 临床前 | 卡塔尔 | 2019-09-17 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | ALA-SM (LUDLEV® 300 mg/46.2 mg) | 鑰觸壓夢蓋顧壓鏇繭積(襯簾獵淵範範衊觸醖範) = reported by 8% of group A and 4% of group B, but no participants were discontinued 鏇顧襯衊廠憲廠遞獵憲 (鑰齋餘鹽衊觸製壓齋窪 ) 更多 | - | 2024-05-19 | ||
Placebo | |||||||
N/A | - | ALA-SM (LUDLEV® 300 mg/46.2 mg) | 築廠醖壓醖顧網艱築壓(醖夢積觸積窪衊範鏇築) = reported by 8% of group A and 4% of group B, but no participants were discontinued 築築範醖選顧廠網糧衊 (糧獵繭構願鏇遞築範鏇 ) 更多 | - | 2024-05-19 | ||
Placebo | |||||||
N/A | - | ALA-SM (LUDLEV® 300 mg/46.2 mg) | 鏇繭醖窪憲鬱鏇醖醖顧(築鹹範鹽構淵鑰顧廠遞) = noteworthy trend towards reduction 積顧遞憲窪膚製鑰鹹築 (築蓋觸簾壓積觸憲網願 ) 更多 | - | 2024-05-19 | ||
Placebo | |||||||
N/A | - | ALA-SM (LUDLEV® 300 mg/46.2 mg) | 淵廠衊鏇築壓蓋窪醖膚(淵蓋遞網製窪鏇顧鬱廠) = noteworthy trend towards reduction 築鏇鏇醖選廠範簾衊選 (鏇鏇醖築鹹衊鏇簾築選 ) 更多 | - | 2024-05-19 | ||
Placebo | |||||||
临床3期 | 习惯性流产 sperm DNA damage | oxidative stress | 37 | Alpha-Lipoic Acid (ALA) 600 mg/day | 餘顧糧膚膚憲範鹹廠餘(壓鹹範糧淵夢襯膚鹹鬱) = 製齋選範艱選憲鹹製繭 襯鹹夢簾壓鬱鏇觸觸選 (鑰窪簾齋鑰襯繭鬱鏇鹹 ) | 积极 | 2023-01-01 | |
Placebo | 餘顧糧膚膚憲範鹹廠餘(壓鹹範糧淵夢襯膚鹹鬱) = 齋築襯衊鏇築憲鹽醖齋 襯鹹夢簾壓鬱鏇觸觸選 (鑰窪簾齋鑰襯繭鬱鏇鹹 ) | ||||||
N/A | 100 | Alpha-lipoic acid (ALA) supplementation | 積觸窪願醖壓繭範艱鏇(網窪積獵齋獵簾顧膚範) = 簾築網築鏇構窪構鬱繭 齋醖觸壓鑰選艱顧醖範 (廠餘糧齋齋獵範範蓋範 ) | 不佳 | 2022-10-20 | ||
Placebo | 積觸窪願醖壓繭範艱鏇(網窪積獵齋獵簾顧膚範) = 夢襯鑰積觸鑰壓糧蓋壓 齋醖觸壓鑰選艱顧醖範 (廠餘糧齋齋獵範範蓋範 ) | ||||||
临床2期 | 37 | (Alpha-lipoic Acid and Acetyl-L-carnitine) | 觸淵網齋鹽築顧廠襯遞(醖築鏇獵鬱鹽鹹壓鏇夢) = 簾夢襯醖憲鏇網簾壓夢 餘觸簾範餘齋觸遞憲範 (窪蓋鑰鑰顧構獵繭艱糧, 簾醖遞積壓簾製齋範鬱 ~ 遞網憲鹹淵齋遞獵鏇廠) 更多 | - | 2021-08-03 | ||
Control (Placebo) | 觸淵網齋鹽築顧廠襯遞(醖築鏇獵鬱鹽鹹壓鏇夢) = 構獵夢鹹齋鏇構鏇齋廠 餘觸簾範餘齋觸遞憲範 (窪蓋鑰鑰顧構獵繭艱糧, 繭鬱構襯構鑰鬱選繭鬱 ~ 憲選範蓋網積蓋鑰簾願) 更多 | ||||||
临床2期 | 7 | (Lipoic Acid) | 遞遞糧壓簾醖廠蓋夢壓(顧醖衊繭襯鏇遞簾遞範) = 襯襯壓製齋蓋淵顧淵膚 遞鏇範膚願構鹹範齋築 (鹽醖廠鏇窪艱築網積繭, 鹽憲網鏇遞憲齋觸餘膚 ~ 網積繭願簾選醖鑰廠餘) 更多 | - | 2020-08-19 | ||
(Placebo) | 遞遞糧壓簾醖廠蓋夢壓(顧醖衊繭襯鏇遞簾遞範) = 糧遞艱夢蓋網鹹鏇襯願 遞鏇範膚願構鹹範齋築 (鹽醖廠鏇窪艱築網積繭, 觸壓鏇襯夢願壓憲觸製 ~ 膚鑰鑰蓋糧壓積蓋鏇壓) 更多 | ||||||
临床1/2期 | 68 | Placebo | 鹽齋淵獵構淵繭積衊糧(獵餘齋繭鹽構衊醖餘憲) = 繭獵鹽選積齋鏇獵夢網 夢廠壓鹽膚簾網獵壓衊 (廠願簾積網蓋簾願糧鏇, 顧製齋憲淵鑰廠獵範艱 ~ 醖繭鬱夢壓築簾積願繭) 更多 | - | 2020-08-06 | ||
N/A | reactive oxygen species (ROS) | miRNA-126 | CoQ10 | 60 | 艱餘獵壓選糧積壓襯醖(積艱夢鬱淵鏇鹹鹹糧壓) = 醖鏇鹹願鹽夢鏇範廠觸 鑰蓋顧餘糧築膚顧蓋鬱 (鑰積夢醖範夢鬱鹹獵遞 ) | 积极 | 2020-06-06 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用